Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348169 | 0.82 | SMN1; SMN2 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL349134 | 0.78 | OPRM1 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL22638185 | 0.77 | ME2 (0.51) | SLC6A4 | |
| SCHEMBL5444355 | 0.76 | SMN1; SMN2 (0.54) | OPRM1HPGDSMN1; SMN2 | |
| SCHEMBL27676379 | 0.76 | HPGD (0.44) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL25273965 | 0.76 | GRM1 (0.43) | SLC6A4 | |
| SCHEMBL28763231 | 0.75 | OPRM1 (0.37) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL5449861 | 0.73 | HSD11B1 (0.62) | — | |
| SCHEMBL5442809 | 0.73 | NR1H2 (0.39) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL3554487 | 0.73 | CHRM4 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | OPRM1 612/4885OPRD1 399/4885OPRK1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.